Osteoporosis therapy with denosumab in organ transplant recipients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F18%3A00076892" target="_blank" >RIV/00023001:_____/18:00076892 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.frontiersin.org/articles/10.3389/fendo.2018.00162/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fendo.2018.00162/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fendo.2018.00162" target="_blank" >10.3389/fendo.2018.00162</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Osteoporosis therapy with denosumab in organ transplant recipients

Popis výsledku v původním jazyce

Objective: Osteoporosis and fragility fractures represent serious complications for the solid organ transplant population. The recommended osteoporosis therapy for organ recipients involves supplementation with calcium and vitamin D and bisphosphonate administration. However, these options can prove limited for patients with impaired renal function. An alternative therapy option is offered by denosumab, a monoclonal antibody that targets receptor activator of nuclear factor kappa-B ligand. Results: After denosumab therapy, L-spine T-scores improved across the whole group, ranging from -2.7 +/- 0.09 to -1.8 +/- 1.0 (p &lt; 0.001). T-score values for the proximal femur increased from -2.5 +/- 0.8 to -2.0 +/- 0.7 after the therapy (p &lt; 0.01). We observed only a mild, statistically insignificant improvement in distal forearm T-scores. The mean increase in L-spine bone mineral density (BMD) was 11.5 +/- 6.2% in subjects with osteoporosis at this site and 10.4 +/- 6.1% in the case of all patients. BMD of the proximal femur increased by 10.4 +/- 8.3% in patients with osteoporosis and by 7.5 +/- 7.3% in all patients. Denosumab therapy decreased the prevalence of osteoporosis in the L-spine from 75 to 27% (p &lt; 0.001) and proximal femur osteoporosis from 54 to 36% (p &lt; 0.05). Denosumab therapy reduced elevated levels of osteocalcin and beta-crosslaps (beta CTX) in comparison with baseline levels (p &lt; 0.001) across the whole group of graft recipients. Conclusion: Denosumab therapy was well-tolerated and improved bone density in our group of solid organ transplant recipients. The indications are that denosumab could be a viable therapeutic option for transplanted patients with osteoporosis, especially in those with renal function impairment or bisphosphonate intolerance.

Název v anglickém jazyce

Osteoporosis therapy with denosumab in organ transplant recipients

Popis výsledku anglicky

Objective: Osteoporosis and fragility fractures represent serious complications for the solid organ transplant population. The recommended osteoporosis therapy for organ recipients involves supplementation with calcium and vitamin D and bisphosphonate administration. However, these options can prove limited for patients with impaired renal function. An alternative therapy option is offered by denosumab, a monoclonal antibody that targets receptor activator of nuclear factor kappa-B ligand. Results: After denosumab therapy, L-spine T-scores improved across the whole group, ranging from -2.7 +/- 0.09 to -1.8 +/- 1.0 (p &lt; 0.001). T-score values for the proximal femur increased from -2.5 +/- 0.8 to -2.0 +/- 0.7 after the therapy (p &lt; 0.01). We observed only a mild, statistically insignificant improvement in distal forearm T-scores. The mean increase in L-spine bone mineral density (BMD) was 11.5 +/- 6.2% in subjects with osteoporosis at this site and 10.4 +/- 6.1% in the case of all patients. BMD of the proximal femur increased by 10.4 +/- 8.3% in patients with osteoporosis and by 7.5 +/- 7.3% in all patients. Denosumab therapy decreased the prevalence of osteoporosis in the L-spine from 75 to 27% (p &lt; 0.001) and proximal femur osteoporosis from 54 to 36% (p &lt; 0.05). Denosumab therapy reduced elevated levels of osteocalcin and beta-crosslaps (beta CTX) in comparison with baseline levels (p &lt; 0.001) across the whole group of graft recipients. Conclusion: Denosumab therapy was well-tolerated and improved bone density in our group of solid organ transplant recipients. The indications are that denosumab could be a viable therapeutic option for transplanted patients with osteoporosis, especially in those with renal function impairment or bisphosphonate intolerance.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Frontiers in endocrinology

ISSN

1664-2392

e-ISSN

—

Svazek periodika

9

Číslo periodika v rámci svazku

April

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

8

Strana od-do

"art. no. 162"

Kód UT WoS článku

000430203100001

EID výsledku v databázi Scopus

2-s2.0-85045727991